The Japanese pharmaceutical industry, a vital component of global innovation, faces a talent gap that resonates across multinational corporations. While Japan possesses a wealth of highly skilled professionals, a notable communication disparity impedes recruitment and career advancement, particularly in global…
BUSINESS
Mochida Files EPA Agent Epadel in China
Mochida Pharmaceutical said on July 2 that it has filed for Chinese regulatory approval of its high-purity ethyl icosapentate (EPA) agent Epadel S (ethyl icosapentate), which is being developed in China jointly with a local subsidiary of Sumitomo Pharma. The…
To read the full story
Related Article
- Mochida, Meiji Expand Epadel Sales Collab to ASEAN, Taiwan
September 2, 2024
- Mochida, Meiji Adds China for Epadel Sales Collaboration
April 4, 2024
- Epadel to Enter Clinical Study in China: Mochida, Sumitomo Dainippon
July 18, 2018
BUSINESS
- Taking on Solid Tumors - 3: J&J to Soon Have 3 Bispecifics in Japan as Rybrevant Gathers Pace
May 30, 2025
- Shingles Heavily Pitched for GPs as It Enters NIP: Intage April Data
May 30, 2025
- Eisai Wins Lenvima Patent Suit in US, Barring Generic to 2036
May 30, 2025
- Bimzelx Now Available as Single-Injection Option: UCB Japan
May 30, 2025
- Mitsubishi Re-Files NeuroDerm’s Parkinson’s Drug in US
May 30, 2025
Following the launch of two new therapies since last year, Japan has seen fresh moves in drug development for amyotrophic…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…